Catalyst Pharma Files Routine 8-K, No New Material Events
Ticker: CPRX · Form: 8-K · Filed: Feb 29, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, routine-filing
TL;DR
**Catalyst Pharma filed a standard 8-K, nothing new to see here.**
AI Summary
Catalyst Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting on 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates no specific new material events or financial changes, but rather serves as a general update on the company's status and confirms its details such as its incorporation in Delaware and business address at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.
Why It Matters
This routine filing provides transparency on Catalyst Pharmaceuticals' corporate information but does not signal any immediate operational or financial shifts that would impact investors.
Risk Assessment
Risk Level: low — The filing is routine and does not disclose any new risks or material events.
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- Delaware (company) — State of incorporation
- February 28, 2024 (date) — Date of earliest event reported
- 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134 (company) — Principal executive offices address
- 001-33057 (company) — Commission File Number
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 28, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is CATALYST PHARMACEUTICALS, INC.
In which state or other jurisdiction is Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Catalyst Pharmaceuticals, Inc.?
The business address is 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.
What items were reported in this 8-K filing?
The items reported were 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-02-28 20:37:00
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d776053d8k.htm (8-K) — 24KB
- d776053dex991.htm (EX-99.1) — 119KB
- 0001193125-24-051235.txt ( ) — 277KB
- cprx-20240228.xsd (EX-101.SCH) — 3KB
- cprx-20240228_lab.xml (EX-101.LAB) — 18KB
- cprx-20240228_pre.xml (EX-101.PRE) — 11KB
- d776053d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on February 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: February 28, 2024 3